1. Introduction
===============

No particular regimen is considered standard therapy for widespread metastatic melanoma, and effectiveness of single-agent interventions has been questioned \[[@B1-healthcare-01-00096]\]. Here, we report a new approach with intralesional interleukin-2 (IL-2) and V-beam pulsed dye laser for the treatment of scalp melanoma metastases.

2. Case Report
==============

The patient was a 61-year-old man. Twenty-two years ago, a primary melanoma was removed from his neck. Eleven years later, a second primary melanoma developed on his scalp, and was surgically excised. Seven years later, a third melanoma (superficial spreading type) developed on the scalp (Clark level III, Breslow thickness 0.9 mm, and mitotic rate 2/mm^2^), and was treated with wide local excision and sentinel lymph node biopsy. Two lymph nodes harvested were negative. Half a year later, multiple in-transit metastases appeared on his scalp without signs of distant metastases. The lesions were surgically excised. However, multiple in-transit metastases continued to develop in the region rapidly. Thereafter, surgical excision and topical imiquimod 5% were initiated resulting in complete resolution of one lesion, whereas two others persisted.

The patient was referred to our institution ([Figure 1](#healthcare-01-00096-f001){ref-type="fig"}A). The melanoma was genetically wild-type. Treatment began with systemic granulocyte-macrophage colony-stimulating factor (GMCSF) (250 mcg/day; alternating between 2 weeks of treatments and cessations), topical imiquimod 5% (twice/day), V-beam pulsed dye laser (every 2--4 weeks; 595 nm; 10-mm spot size), and periodic punch excisions from June through November 2010. Despite improvement, new lesions continued to develop. Intralesional IL-2 injections (6 million IUs, 2--3 times/week) were then added to the therapeutic regimen. Subsequently, within 1 month, all the tumors vanished ([Figure 1](#healthcare-01-00096-f001){ref-type="fig"}A) with pathological confirmation. No severe toxicity was observed, and patient only had flu-like symptoms. Treatment was discontinued in December 2010. The patient remained clinically melanoma-free until July 2011, when a new solitary lesion appeared on vertex scalp. The 0.5 × 0.5-cm lesion was a freely mobile, subcutaneous nodule and was confirmed to be metastatic melanoma. IL-2 injections resumed with the previous protocol for a longer period, and complete response was achieved. By September 2011, biopsy showed no residual cancer in the area.

![(**A1**) In-transit metastasis of melanoma at presentation (referral to our institution); (**A2**) After initial treatment with pulsed dye laser; (**A3**) At the initiation of interleukin-2 injections, in conjunction with continued pulsed dye laser therapy; (**A4**) Four and a half weeks after the addition of interlesional interleukin-2; (**B**) Possible mechanisms of the synergetic effects of intralesional interleukin-2 (IL-2) and local laser therapy.](healthcare-01-00096-g001){#healthcare-01-00096-f001}

3. Results and Discussion
=========================

The management of recurrent melanoma remains challenging. This patient with prolonged but localized in-transit melanoma showed remarkably improved clinical outcome when intralesional IL-2 was added to the interventions. The synergistic effect of IL-2 with V-beam laser is supported by animal models that show enhanced antitumor immunity with judicious combination of immunologic stimulation and laser devitalization of tumor nodules \[[@B2-healthcare-01-00096]\]. The benefits of systemic IL-2 are offset by its toxicities, limiting its usage to selected patients with advanced metastatic melanoma. We demonstrated that intralesional administration of IL-2 in combination with V-beam laser achieved rapid regression of in-transit metastasis with limited adverse effects.

IL-2 induced vascular leakage is advantageous in localized treatment because local edema may initiate tumor necrosis that stimulates the immune response. Furthermore, intralesional injection of IL-2 achieves much higher local concentration and limits systemic adverse effects. Therefore a greater therapeutic effect could be expected. Indeed, studies indicated that intralesional IL-2 therapy was more effective than systemic, perilesional, and distant site IL-2 treatments \[[@B3-healthcare-01-00096]\]. One report showed that a complete local response was achieved in 69% of metastasized melanoma patients (33/48) by intratumorally injection of IL-2 \[[@B4-healthcare-01-00096]\].

Preferential absorption of laser radiance by hemoglobin and the subsequent conversion of light energy into thermal energy may cause blood vessel coagulation \[[@B5-healthcare-01-00096]\], which may enhance the local edematous and ischemic effect of IL-2. In addition, cancer cells are more vulnerable than normal cells to hyperthermia-induced cellular damage \[[@B6-healthcare-01-00096]\]. Considerable improvement in clinical outcome has been reported after hyperthermic therapy in tumors of many types, including melanoma \[[@B6-healthcare-01-00096]\]. [Figure 1](#healthcare-01-00096-f001){ref-type="fig"}B summarizes the possible synergetic effect of intralesional IL-2 and V-beam therapy.

4. Conclusions
==============

Our results indicate that this combined therapy is a promising strategy for the treatment of in-transit metastatic melanoma. Further study in a larger patient population is warranted.
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